Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?

Despite the advent of public health initiatives in recent years, North America and Central and Eastern Europe continue to record some of the highest lung cancer incidence rates globally [1]. Non-small cell lung cancer (NSCLC) accounts for an estimated 80 –90% of all lung cancers, with adenocarcinomas representing an increasing healthcare priority across the USA and Europe [2].

Source: Lung Cancer - April 19, 2020 Category: Cancer & Oncology Authors: Sanjay Popat, Christian Groh é, Jesus Corral, Martin Reck, Silvia Novello, Maya Gottfried, Dejan Radonjic, Rolf Kaiser Tags: Review Source Type: research